INVO Bioscience, Inc.

Equities

INVO

US44984F4019

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 21:00:00 17/05/2024 BST 5-day change 1st Jan Change
0.985 USD -1.50% Intraday chart for INVO Bioscience, Inc. -2.48% -27.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Top Premarket Decliners MT
Sector Update: Health Care Stocks Retreating Late Afternoon MT
Top Midday Gainers MT
Traders Digest Earnings After Rate-Driven Losses, US Equity Futures Rebound Slightly MT
Top Premarket Gainers MT
INVO Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
INVO Bioscience, Inc. announced that it has received $0.5 million in funding from FirstFire Capital Management LLC CI
INVO Bioscience, Inc. announced that it expects to receive $0.5 million in funding from FirstFire Capital Management LLC CI
Certain Options of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024. CI
Certain Warrants of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024. CI
Certain Common Stock of INVO Bioscience, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2024. CI
INVO Bioscience, Inc. announced that it expects to receive $5 million in funding from NAYA Biosciences Inc. CI
NAYA Biosciences Inc. Announces Publication of New Data for its CD38-targeted Flex-NK Bispecific Antibody in the American Society of Hematology's Blood Journal CI
Top Premarket Gainers MT
Earnings Flash (INVO) INVO BIOSCIENCE Reports Q3 Revenue $974,894 MT
INVO Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks MT
Transcript : INVO Bioscience, Inc., NAYA Biosciences Inc. - Special Call
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Mixed in Monday Afternoon Trading MT
INVO Bioscience Shares Skyrocket After Signing Deal to Buy NAYA Biosciences MT
Wall Street Set to Open Lower Monday as National Activity Index Shows Near-Historic Economic Growth MT
NAYA Biosciences entered into an agreement to acquire INVO Bioscience, Inc. in a reverse merger transaction for $90.7 million. CI
Transcript : INVO Bioscience, Inc., Q2 2023 Earnings Call, Aug 14, 2023
Earnings Flash (INVO) INVO BIOSCIENCE Posts Q2 Revenue $315,902, vs. Street Est of $450,000 MT
Chart INVO Bioscience, Inc.
More charts
INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Company’s flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The Company operates three INVO Centers in North America.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.985
Average target price
-
Consensus